skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Informa pharma logo

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

PharmaLogo
Search Icon Report storeRecommendationsProduct loginProductLogin
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

44 Total results for product and free and sample content found

Pharmaprojects

Drug Development for Eating Disorders and Obesity – Weighing Up the Difference. Part II

By Pippa Nutkins 18 Apr 2018

After our review of the drug development landscape for eating disorders, we investigated the latest research trends and pharmacological interventions for the escalating global obesity epidemic. The argument that eating disorders and obesity are similarly manifested in genetic, metabolic and psychological origins could be an important consideration for drug development in these two complex indications. Are such similarities reflected in the drug development pipelines and what are the prospects for these multifactorial diseases?

Topic Drug development landscape

Read blog

Pharmaprojects

Drug Development for Eating Disorders and Obesity - Weighing Up the Difference Part II

By Pippa Nutkins 02 Mar 2018

We investigated the latest research trends and pharmacological interventions for the escalating global obesity epidemic. The argument that eating disorders and obesity are similarly manifested in genetic, metabolic and psychological origins could be an important consideration for drug development in these two complex indications.

Topic Drug development landscape

Read blog

Pharmaprojects

Drug Development for Eating Disorders and Obesity - Weighing Up the Difference Part II

By Pippa Nutkins 02 Mar 2018

We investigated the latest research trends and pharmacological interventions for the escalating global obesity epidemic. The argument that eating disorders and obesity are similarly manifested in genetic, metabolic and psychological origins could be an important consideration for drug development in these two complex indications.

Topic Drug development landscape

Read blog

Pharmaprojects, Trialtrove

Spotlight on Huntington's Disease for #Rare Disease Day

By Judy Adair 28 Feb 2018

February 28, 2018 is the eleventh international #Rare Disease Day.  This day is designed to raise awareness about rare diseases and their impact on patient’s lives to public and decision-makers in government and health fields.  Scrutiny of rare diseases is vital as there are approximately 7,000 different types of rare diseases and approximately 80 percent are caused by faulty genes [1].  This paper will focus on one, Huntington’s Disease (HD).

Topic Rare Disease

Read blog

Pharmaprojects

Drug Development for Eating Disorders and Obesity - Weighing Up the Difference. Part I

By Angela Kwan 27 Feb 2018

As Eating Disorder Awareness Week gets under way for 2018, we reviewed the latest pharmacological interventions for three of the most common eating disorders (anorexia nervosa, bulimia nervosa and binge eating disorder) and obesity in a two part blog series, to uncover the emerging trends in these fields and consider what it might mean for future therapeutic development.

Topic Drug development landscape

Read blog

Trialtrove, Pharmaprojects

2018 - the year of successful migraine prophylaxis therapies

By Daniel Digaudio 13 Feb 2018

It is essential that a truly effective prophylactic migraine medicine is found. Many currently available migraine therapies are acute and provide the patient with some relief after the onset of a migraine, whereas preventative medicines are extremely limited and not entirely effective. This blog will look at the past, present, and future of migraine prophylaxis.

Topic Drug development landscape

Read blog

Trialtrove

Approaching Dementia from All Angles

By Laurie Withington 20 Dec 2017

There have been numerous failures of Alzheimer’s dementia drugs in the past five years.

Topic Alzheimers

Read blog

Trialtrove

Immuno-Oncology Combination Trials Now Easily Accessible in Trialtrove

By Maria A. Berezina and Rachel Meighan-Mantha 28 Sep 2017

Immuno-oncology (IO) is one of the most active area of clinical development.

Topic Cancer Clinical trials blog immuno-oncology

Read blog

Trialtrove, Pharmaprojects

Non-Radiographic Axial Spondyloarthritis: Expanding Trialtrove Options in an Evolving Clinical Space

By Laura Runkel 18 Sep 2017

As clinical and diagnostic parameters evolve over time, Trialtrove strives to reflect them in our patient segments and disease coverage.  

Topic Clinical trials blog

Read blog
Show More

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.
General enquiry

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop now